{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T15:06:02Z","timestamp":1770995162637,"version":"3.50.1"},"reference-count":28,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Takeda Pharmaceutical Company Limited"},{"name":"Good Publication Practice (GPP).<\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunological Medicine"],"DOI":"10.1080\/25785826.2025.2607878","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T14:03:47Z","timestamp":1770991427000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics, safety and tolerability, and efficacy of hyaluronidase-facilitated subcutaneous immunoglobulin 10% (HyQvia\n                    <sup>\u00ae<\/sup>\n                    ) in Japanese patients with primary immunodeficiency diseases"],"prefix":"10.1080","author":[{"given":"Hirokazu","family":"Kanegane","sequence":"first","affiliation":[{"name":"Department of Child Health and Development, Institute of Science Tokyo","place":["Tokyo, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Ishimura","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University","place":["Fukuoka, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisuke","family":"Suganuma","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Immunology, Allergy, Saitama Children\u2019s Medical Center","place":["Saitama, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Imagawa","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease and Immunology, Kanagawa Children\u2019s Medical Center","place":["Kanagawa, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Hoshina","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, University of Occupational and Environmental Health, Japan","place":["Fukuoka, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Kawai","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Shizuoka Children\u2019s Hospital","place":["Shizuoka, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Ohnishi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Graduate School of Medicine, Gifu University","place":["Gifu, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hiroshima University Graduate School of Biomedical and Health Sciences","place":["Hiroshima, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Company Limited","place":["Osaka, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentarou","family":"Kudou","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Company Limited","place":["Osaka, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Russo-Schwarzbaum","sequence":"additional","affiliation":[{"name":"Baxalta Innovations GmbH, a Takeda company","place":["Vienna, Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Immanuel","family":"Freedman","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc","place":["Cambridge, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"McCoy","sequence":"additional","affiliation":[{"name":"Baxalta Innovations GmbH, a Takeda company","place":["Vienna, Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoyang","family":"Li","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc","place":["Cambridge, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kuga","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Company Limited","place":["Osaka, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"e_1_3_7_2_1","doi-asserted-by":"publisher","DOI":"10.70962\/jhi.20250002"},{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.70962\/jhi.20250003"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.07.053"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.86"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-021-01160-x"},{"issue":"5","key":"e_1_3_7_7_1","first-page":"76","article-title":"New insights in the use of immunoglobulins for the management of immune deficiency (PID) patients","volume":"6","author":"Krivan G","year":"2017","unstructured":"Krivan G, Jolles S, Granados EL, et al. New insights in the use of immunoglobulins for the management of immune deficiency (PID) patients. Am J Clin Exp Immunol. 2017;6(5):76\u201383.","journal-title":"Am J Clin Exp Immunol"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-022-08950-0"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2009.04027.x"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.06.021"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-023-01321-y"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-023-01470-2"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S31136"},{"key":"e_1_3_7_14_1","unstructured":"US Food and Drug Administration. HYQVIA: FDA; 2024. https:\/\/www.fda.gov\/vaccines-blood-biologics\/approved-blood-products\/hyqvia"},{"key":"e_1_3_7_15_1","unstructured":"European Medicines Agency. HyQvia: EPAR - product information: EMA; 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/hyqvia-epar-product-information_en.pdf"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-024-00904-9"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-024-01769-8"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-017-0464-9"},{"key":"e_1_3_7_19_1","unstructured":"US Food and Drug Administration. Guidance for industry: safety efficacy and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency: U.S. Department of Health and Human Services Center for Biologics Evaluation and Research; 2008. https:\/\/www.fda.gov\/media\/124333\/download"},{"key":"e_1_3_7_20_1","unstructured":"European Medicines Agency. Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg) - EMA\/CHMP\/BPWP\/94033\/2007 rev. 4: Committee for Medicinal Products for Human Use; 2021. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-human-normal-immunoglobulin-intravenous-administration-ivig-rev-4_en.pdf"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltae001"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(87)90494-6"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3476(99)70246-5"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-016-0298-x"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-025-01862-6"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-013-9985-z"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-019-00705-5"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-022-00726-7"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03259507"}],"container-title":["Immunological Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/25785826.2025.2607878","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T14:03:49Z","timestamp":1770991429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/25785826.2025.2607878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":28,"alternative-id":["10.1080\/25785826.2025.2607878"],"URL":"https:\/\/doi.org\/10.1080\/25785826.2025.2607878","relation":{},"ISSN":["2578-5826"],"issn-type":[{"value":"2578-5826","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=timm20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=timm20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-08-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}